- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Patent holdings for IPC class A61K 47/60
Total number of patents in this class: 3830
10-year publication summary
119
|
225
|
351
|
432
|
391
|
434
|
417
|
403
|
384
|
249
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Nektar Therapeutics | 438 |
88 |
Hanmi Pharm. Co., Ltd. | 574 |
71 |
The Regents of the University of California | 20059 |
59 |
Bristol-myers Squibb Company | 4867 |
47 |
Ascendis Pharma A/S | 182 |
43 |
The Johns Hopkins University | 5709 |
42 |
Massachusetts Institute of Technology | 10102 |
40 |
Ascendis Pharma Growth Disorders A/S | 56 |
39 |
Board of Regents, The University of Texas System | 5849 |
34 |
Synthorx, Inc. | 78 |
33 |
Amgen Inc. | 4106 |
26 |
Quiapeg Pharmaceuticals AB | 45 |
26 |
Ascendis Pharma Bone Diseases A/S | 47 |
25 |
Janssen Pharmaceutica N.V. | 3369 |
24 |
NOK Corporation | 2229 |
23 |
The Board of Trustees of the Leland Stanford Junior University | 6451 |
22 |
Northwestern University | 3408 |
22 |
Ambrx, Inc. | 183 |
20 |
Yale University | 2401 |
20 |
SeaGen Inc | 591 |
20 |
Other owners | 3106 |